Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

By

Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

Tivantinib Fails to Improve Overall Survival As Second-Line Treatment in Liver Cancer

By

Previous studies have demonstrated tivantinib prolonged progression-free survival and overall survival in hepatocellular carcinoma.

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

By

The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.

Regorafenib Improves Survival in Unresectable Liver Cancer

Regorafenib Improves Survival in Unresectable Liver Cancer

By

The kinase inhibitor regorafenib conferred improved overall survival in patients with unresectable hepatocellular carcinoma (HCC).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs